Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Konvinse KC, Phillips EJ, White KD, Trubiano JA.

Curr Opin Infect Dis. 2016 Dec;29(6):561-576.

2.

The signaling involved in autophagy machinery in keratinocytes and therapeutic approaches for skin diseases.

Li L, Chen X, Gu H.

Oncotarget. 2016 Aug 2;7(31):50682-50697. doi: 10.18632/oncotarget.9330. Review.

3.

Antiviral drug allergy.

Milpied-Homsi B, Moran EM, Phillips EJ.

Immunol Allergy Clin North Am. 2014 Aug;34(3):645-62, ix. doi: 10.1016/j.iac.2014.04.011. Review.

4.

Cutaneous Adverse Reactions to Highly Antiretroviral Therapy in HIV-Positive Patients.

Pistone G, Pistone A, Sorbello D, Viviano E, Bongiorno MR.

Case Rep Dermatol. 2014 May 17;6(2):145-9. doi: 10.1159/000354030.

5.

Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.

Yunihastuti E, Widhani A, Karjadi TH.

Asia Pac Allergy. 2014 Jan;4(1):54-67. doi: 10.5415/apallergy.2014.4.1.54. Review.

6.

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Usach I, Melis V, Peris JE.

J Int AIDS Soc. 2013 Sep 4;16:1-14. doi: 10.7448/IAS.16.1.18567. Review.

7.

Severe skin rash with lamivudine in HIV infected patients: some unusual case reports.

Modak D, Guha SK.

Indian J Pharmacol. 2013 May-Jun;45(3):298-300. doi: 10.4103/0253-7613.111906.

8.

HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Shimane K, Kawaji K, Miyamoto F, Oishi S, Watanabe K, Sakagami Y, Fujii N, Shimura K, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

Antimicrob Agents Chemother. 2013 Aug;57(8):4035-8. doi: 10.1128/AAC.00237-13.

9.

Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytes.

Dong Q, Oh JE, Yi JK, Kim RH, Shin KH, Mitsuyasu R, Park NH, Kang MK.

Int J Mol Med. 2013 Jun;31(6):1305-12. doi: 10.3892/ijmm.2013.1327.

10.

Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.

Mudzviti T, Sibanda M, Gavi S, Maponga CC, Morse GD.

J Infect Dev Ctries. 2012 Nov 26;6(11):806-8. doi: 10.3855/jidc.1908.

11.

Hypersensitivity reactions to HIV therapy.

Chaponda M, Pirmohamed M.

Br J Clin Pharmacol. 2011 May;71(5):659-71. doi: 10.1111/j.1365-2125.2010.03784.x. Review.

12.

Long-term safety from the raltegravir clinical development program.

Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY.

Curr HIV Res. 2011 Jan;9(1):40-53.

13.

The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

Israr M, Mitchell D, Alam S, Dinello D, Kishel JJ, Meyers C.

HIV Med. 2011 Mar;12(3):145-56. doi: 10.1111/j.1468-1293.2010.00863.x.

Items per page

Supplemental Content

Support Center